Vireo Growth (VREOF) Retained Earnings (2020 - 2026)
Vireo Growth (VREOF) reported Retained Earnings of -$319.9 million for Q1 2026, down 34.44% on a YoY basis from -$488.0 million in Q1 2025, and down 6.78% sequentially from -$299.6 million in Q4 2025.
Vireo Growth (VREOF) Retained Earnings (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Retained Earnings data on file, last reported at -$319.9 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 34.44% year-over-year to -$319.9 million; the trailing twelve-month figure through Mar 2026 stood at -$319.9 million (down 34.44% YoY), and the FY2025 full-year result was -$299.6 million, down 29.45% from the prior year.
- Retained Earnings fell to -$319.9 million in Q1 2026, from -$299.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$150.0 million in Q1 2022 to a low of -$319.9 million in Q1 2026.
- A 5-year average of -$217.0 million and a median of -$210.1 million in 2024 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings plunged 37.96% in 2022 and decreased 8.49% in 2024, its largest moves.
- Tracing VREOF's Retained Earnings over 5 years: stood at -$177.9 million in 2022, then declined by 14.36% to -$203.4 million in 2023, then fell by 13.77% to -$231.4 million in 2024, then declined by 29.45% to -$299.6 million in 2025, then declined by 6.78% to -$319.9 million in 2026.
- Business Quant data shows VREOF's Retained Earnings at -$319.9 million in Q1 2026, -$299.6 million in Q4 2025, and -$279.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -319.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -319.90 Mn |
| Dec 31, 2025 | -299.60 Mn |
| Sep 30, 2025 | -279.18 Mn |
| Jun 30, 2025 | -252.88 Mn |
| Mar 31, 2025 | -237.94 Mn |
| Dec 31, 2024 | -231.44 Mn |
| Sep 30, 2024 | -215.73 Mn |
| Jun 30, 2024 | -210.81 Mn |
| Mar 31, 2024 | -210.14 Mn |
| Dec 31, 2023 | -203.43 Mn |
| Sep 30, 2023 | -198.85 Mn |
| Jun 30, 2023 | -193.62 Mn |
| Mar 31, 2023 | -186.29 Mn |
| Dec 31, 2022 | -177.88 Mn |
| Sep 30, 2022 | -164.60 Mn |
| Jun 30, 2022 | -156.17 Mn |
| Mar 31, 2022 | -149.99 Mn |
| Dec 31, 2021 | -135.42 Mn |
| Sep 30, 2021 | -120.44 Mn |
| Jun 30, 2021 | -114.20 Mn |